Bloomberg News

Abbott Reports Two Hepatitis C Relapses in ‘Pilot’ Trial

April 19, 2012

Few relapses were reported among patients taking Abbott Laboratories (ABT:US)’ experimental hepatitis C treatment, according to a study.

The Abbott-funded research, dubbed Pilot, found that 10 of 11 patients who hadn’t received prior treatment were cured 24 weeks after the end of a 12-week treatment on the drugmaker’s hepatitis C drugs ABT-072 and ABT-450 with ribavirin, the Abbott Park, Illinois-based company said today in a statement.

After 36 weeks, another patient relapsed, while no more relapses were observed after 48 weeks, the company said.

To contact the reporter on this story: Makiko Kitamura in Barcelona, Spain, via mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net


Tim Cook's Reboot
LIMITED-TIME OFFER SUBSCRIBE NOW

Companies Mentioned

  • ABT
    (Abbott Laboratories)
    • $43.59 USD
    • -0.10
    • -0.23%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus